Targeting High Mobility Group Box 1 in Subarachnoid Hemorrhage : A Systematic Review by Muhammad, Sajjad et al.
 International Journal of 
Molecular Sciences
Review
Targeting High Mobility Group Box 1 in
Subarachnoid Hemorrhage: A Systematic Review
Sajjad Muhammad 1,2,* , Shafqat Rasul Chaudhry 3, Ulf Dietrich Kahlert 1, Martin Lehecka 2,
Miikka Korja 2, Mika Niemelä 2 and Daniel Hänggi 1
1 Department of Neurosurgery, Heinrich-Heine University Medical Center, 40225 Düsseldorf, Germany;
ulf.kahlert@med.uni-duesseldorf.de (U.D.K.); daniel.haenggi@med.uni-duesseldorf.de (D.H.)
2 Department of Neurosurgery, University of Helsinki and Helsinki University Hospital,
00014 Helsinki, Finland; martin.lehecka@hus.fi (M.L.); miikka.korja@hus.fi (M.K.);
mika.niemela@hus.fi (M.N.)
3 Shifa College of Pharmaceutical Sciences, Shifa Tameer-e-Millat University, Islamabad 44000, Pakistan;
shafqatrasul@yahoo.com
* Correspondence: sajjad.muhammad@med.uni-duesseldorf.de; Tel.: +49-151-6846-0755
Received: 19 March 2020; Accepted: 11 April 2020; Published: 14 April 2020


Abstract: Aneurysmal subarachnoid hemorrhage (aSAH) is a complex and potentially deadly disease.
Neurosurgical clipping or endovascular coiling can successfully obliterate ruptured aneurysms in
almost every case. However, despite successful interventions, the clinical outcomes of aSAH patients
are often poor. The reasons for poor outcomes are numerous, including cerebral vasospasm (CVS),
post-hemorrhagic hydrocephalus, systemic infections and delayed cerebral ischemia. Although
CVS with subsequent cerebral ischemia is one of the main contributors to brain damage after
aSAH, little is known about the underlying molecular mechanisms of brain damage. This review
emphasizes the importance of pharmacological interventions targeting high mobility group box 1
(HMGB1)-mediated brain damage after subarachnoid hemorrhage (SAH) and CVS. We searched
Pubmed, Ovid medline and Scopus for “subarachnoid hemorrhage” in combination with “HMGB1”.
Based on these criteria, a total of 31 articles were retrieved. After excluding duplicates and selecting
the relevant references from the retrieved articles, eight publications were selected for the review of
the pharmacological interventions targeting HMGB1 in SAH. Damaged central nervous system cells
release damage-associated molecular pattern molecules (DAMPs) that are important for initiating,
driving and sustaining the inflammatory response following an aSAH. The discussed evidence
suggested that HMGB1, an important DAMP, contributes to brain damage during early brain injury
and also to the development of CVS during the late phase. Different pharmacological interventions
employing natural compounds with HMGB1-antagonizing activity, antibody targeting of HMGB1 or
scavenging HMGB1 by soluble receptors for advanced glycation end products (sRAGE), have been
shown to dampen the inflammation mediated brain damage and protect against CVS. The experimental
data suggest that HMGB1 inhibition is a promising strategy to reduce aSAH-related brain damage
and CVS. Clinical studies are needed to validate these findings that may lead to the development of
potential treatment options that are much needed in aSAH.
Keywords: subarachnoid hemorrhage; damage-associated molecular pattern molecules (DAMPs);
alarmins; HMGB1 (High mobility group box 1); CVS (Cerebral vasospasm)
1. Introduction
Aneurysmal subarachnoid hemorrhage (aSAH) is a devastating cerebrovascular event that
accounts for only 5% of all stroke events. The mortality rate is approximately 50% (ranging from
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32 to 67%) and affects patients of relatively younger age than the ischemic stroke, depriving society of
potential productive age individuals [1]. Almost one third of the survivors have lifelong disabilities
and cognitive problems [2]. In almost 85% of the cases, a rupture of the intracranial aneurysms causes a
flooding of the subarachnoid space with the extravasated blood and can also even involve deeper brain
parenchyma and ventricles [3]. Intracranial aneurysms are weakened lesions or abnormal dilatations
that form in intracranial blood vessels, usually at arterial bifurcation sites, due to the shear stress
of heightened blood flow pressure and are characterized by chronic inflammation [4]. A growing
body of evidence has suggested that an upregulated inflammatory response in the arterial vessel
walls underlies the development, growth and rupture of intracranial aneurysms [4]. Intracranial
aneurysms usually occur at a frequency of 3–5% in the adult population with a slight prevalence
in females [4]. While an obliteration of the aneurysm from the arterial circulation is achieved by
micro-neurosurgical clipping or endovascular coiling in almost every case [5], the outcomes after aSAH
remain poor. The poor outcomes are mainly related to post-aSAH complications such as cerebral
vasospasm (CVS), hydrocephalus, seizures, delayed ischemic neurological deficits (DIND), cortical
spreading depression, delayed cerebral ischemia (DCI), infections, cardiomyopathy and pulmonary
edema [6]. Most complications occur within the first two weeks after the initial bleeding [7].
The molecular mechanisms behind post-aSAH complications are complex and are likely initiated
at the time of early brain injury (EBI). EBI is a result of transient global ischemia that in turn occurs
when blood transits through the ruptured aneurysm and causes increased intracranial pressure (ICP).
Increased ICP leads to the release of damage-associated molecular pattern molecules (DAMPs) from
damaged or stressed central nervous system cells [5,7,8]. The extravasated blood and its degradation
products also cause damage to various cells in the immediate vicinity with a consequent release
of DAMPs [9]. DAMP receptors are widely expressed in central nervous system cells, including
endothelial cells, neurons, microglia, astrocytes and infiltrating immune cells. The interaction of
DAMPs with receptors such as the receptor for advanced glycation end products (RAGE), the toll-like
receptor (TLR)-2 and TLR-4, may initiate and drive the inflammatory response both in the brain
parenchyma and cerebral blood vessels; hence, this links EBI with delayed inflammation. It is, therefore,
important to identify the molecules that initiate and drive the immune response after aSAH.
High mobility group box 1 (HMGB1) is a classic prototypical protein DAMP that is ubiquitously
expressed in the nucleus under normal conditions in all eukaryotic cells and facilitates transcription,
but behaves as a DAMP once released from necrotic or inflammatory cells [10,11]. The HMGB1
molecule is encoded by around 10,000 base pairs on chromosome 13q12 in humans and is comprised of
214–216 amino acids constituting two DNA binding boxes, box A and box B, and an acidic tail [11,12].
HMGB1 has been known to bind several pattern recognition receptors such as TLR-2, TLR-4 and
RAGE on immune cells to upregulate inflammation [9]. Consequently, HMGB1 has been shown to
be an important mediator and pharmacological target in multiple inflammatory diseases, including
sepsis, ischemia, trauma and arthritis [10,13,14]. Increasing evidence from experimental and clinical
studies has suggested that HMGB1 might be an important target to reduce damage during EBI
and life-threatening post-aSAH complications, including CVS. Here, we systematically reviewed the
literature on the pharmacological targeting of HMGB1 in aSAH and the criteria for the selection of
articles is presented in the Supplementary Materials (Figure S1).
2. Results
2.1. HMGB1 Is Released in Cerebrospinal Fluid (CSF) and Systemic Circulation after aSAH
DAMPs liberated upon damage to the cells of the CNS will ultimately find their way to the CSF as
this fluid is immediately in contact with the CNS tissues. The release of HMGB1 into the cerebrospinal
fluid (CSF) of patients after aSAH was first reported by Nakahara and colleagues in 2009. Interestingly,
elevated HMGB1 levels were higher in the CSF of patients with poor clinical outcomes after aSAH.
Moreover, HMGB1 levels were correlated with the tumor necrosis factor (TNF)-α, interleukin (IL)-6
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and IL-8, suggesting an important role of HMGB1 in ongoing inflammation [15]. Extracellularly
released HMGB1 is recognized by TLR-2, TLR-4, TLR-9, and RAGE [16] and leads to the induction of
inflammatory signals, including nuclear factor kappa B (NF-κB). King and colleagues reported similar
findings showing significant associations between CSF HMGB1 levels and aSAH severity (poorer Hunt
and Hess grades) and disability among aSAH patients [17]. Furthermore, an experimental model
of subarachnoid hemorrhage (SAH) confirmed HMGB1 upregulation and showed that HMGB1 was
translocated into the cytosol of the microglia for active secretion [18]. More interestingly, elevated
HMGB1 levels in systemic circulation were associated with CVS, poor functional outcomes and
mortality one year after the aSAH, thus highlighting the prognostic potential of measuring plasma
HMGB1 [19]. Moreover, HMGB1 levels measured in systemic circulation over a period of two weeks
after the aSAH showed an association with CVS [20]. The elevated levels of HMGB1 were correlated
with blood leukocytes and increased IL-6 levels [20]. Interestingly, HMGB1 levels measured on day
1 after the aSAH were also shown to correlate with elevated IL-10 levels later on day 7 after the
aSAH [21]. Another clinical study described elevated CSF HMGB1 levels in acute hydrocephalus after
the aSAH and strong correlations with different scores of aSAH severity, including Hunt and Hess
grades, the World Federation of Neurological Surgeons (WFNS) score, and the Glasgow Coma Scale
(GCS). Furthermore, HMGB1 levels were correlated with the duration of stay in the intensive care unit
and poor outcomes after 3 months [22]. Wang and colleagues confirmed the association between CSF
HMGB1 levels and poor outcomes after 3 months in a larger cohort of aSAH patients.
DCI mainly affects the clinical outcomes of aSAH patients and has been observed in approximately
30% of patients [23]. DCI is multifactorial and cerebral vasospasm is the primary cause leading to a
DCI. A case series of SAH patients with DCI has shown a significant elevation of HMGB1 compared to
the controls [24]. Moreover, the presence of minor allele G of rs2249825 is an independent predictor of
DCI. Interestingly, this single nucleotide polymorphism of HMGB1 (C/G at 3814) leads to an enhanced
HMGB1 expression and may consequently result in DCI [25].
2.2. Pharmacological Inhibition of HMGB1 Protects against Early Brain Injury after SAH
HMGB1 is released after the SAH and is associated with clinical outcomes and post-SAH
complications. Thus, an evaluation of the blocking of the HMGB1 release during a SAH is warranted.
Sun and colleagues observed an early release of HMGB1 (2 h) from neurons after the SAH [26].
An intraventricular injection of recombinant HMGB1 has been shown to upregulate inflammation
as demonstrated by the upregulation of TLR-4, NF-κB, IL-1β and cleaved Caspase-3. Furthermore,
the in vitro application of the red blood cell breakdown product hemoglobin (Hb) led to the upregulation
and translocation of HMGB1 from the nucleus to the cytoplasm in neuronal cultures. Interestingly,
the application of glycyrrhizic acid, a pharmacological inhibitor of HMGB1, downregulated IL-1β and
thus, prevented the activation of glial cells [26]. Moreover, two other natural compounds, purpurogallin
(a natural phenol) and 4′-O-β-d-glucosyl-5-O-methylvisamminol (4OGOMV), attenuated HMGB1
expression in a double hemorrhagic SAH rat model and effectively decreased CVS and CVS-related
caliber changes in basilar arteries [27,28]. A similar study that employed rhinacanthin-C, an extract
from Rhinacanthus nasutus, ameliorated SAH-associated increases in HMGB1 mRNA and protein levels,
pro-inflammatory cytokines, cleavage of Caspase-3 and Caspase-9, and reduced apoptosis after SAH [29].
Resveratrol administration ameliorated the expression of HMGB1 along with other pro-inflammatory
markers and reduced the brain edema, neuronal apoptosis, and improved neurological deficits at 24 h
after the SAH [30]. Moreover, the increased expression of HMGB1 in vasospastic rat basilar arteries
was observed at days 3, 5 and 7 after the SAH [31]. Li et al. have shown an increased basilar artery
thickness and reduced luminal diameter with the increased expression of HMGB1 protein and mRNA
of pro-inflammatory cytokines; these changes were ameliorated after glycyrrhizic acid supplementation
for three days [32]. Glycyrrhizin supplementation has also been shown to downregulate the HMGB1
and pro-inflammatory markers’ (TNF-α, IL-1β) expression and improve neurological scores in a
pre-chiasmatic SAH model [33]. Interestingly, HMGB1 expression and cytosolic translocation was
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inhibited by the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3)
inhibitor AG490 and reduced brain edema, neuronal apoptosis, and improved neurological function
after an experimental SAH [34].
Apoptosis, a form of programmed cell death, is implicated in SAH and the inhibition of apoptosis
is associated with improved neurological deficits [5,8,35]. HMGB1 has been shown to activate apoptotic
cascades in neurons and endothelial cells via the facilitation of proapoptotic p53 activation [36].
However, a programmed form of necrosis, called necroptosis, is characterized by the rupture of
the cell with the extracellular release of DAMPs such as HMGB1. Intriguingly, receptor-interacting
protein kinase-3 (RIPK-3)-mediated necroptosis in neurons was upregulated after an experimental
SAH and was associated with an increased brain injury and cytosolic translocation of HMGB1 [35].
The inhibition of necroptosis by GSK’872, an inhibitor of RIPK-3, prevented cytosolic translocation
and expression of HMGB1, and necroptosis, which was accompanied by reduced brain edema and
improved neurological scoring [35].
Exosomes are nanovesicles secreted by almost all cells of the body and carry a diverse cargo
consisting of proteins and different types of RNA and DNA, which play important roles in intercellular
communication [36,37]. Exosomes derived from bone marrow mesenchymal stem cells (BMSCs) have
been shown to alleviate the neurological deficits, brain edema and the blood–brain barrier disruption
after an experimental SAH [36]. These BMSCs-derived exosomes reduced early brain injury by
ameliorating the expression of pro-inflammatory molecules such as HMGB1, TLR-4 and TNF-α, and also
reduced the proapoptotic p53 expression [36]. The beneficial effects of BMSCs-derived exosomes were
demonstrated to stem from the increased expression of miRNA129-5p, which downregulated the
inflammation mediated by the HMGB1–TLR-4 pathway during early brain injury [36].
2.3. Anti-HMGB1 Antibodies Confer Protection against CVS
A more effective way to block HMGB1 is via neutralization with anti-HMGB1 antibodies.
The administration of anti-HMGB1 antibodies in an experimental rat model of SAH decreased basilar
artery vasospasm, extracellular translocation and the expression of HMGB1 in smooth muscle cells, as
well as decreased the expression of contractile (endothelin type A (ETA)) receptor, angiotensin-II type
1 (AT1) receptor, protease activated receptor-1 (PAR1, thrombin receptor), thromboxane A2 (TXA2)
receptor), inflammation-associated (TNF-α, IL-6, inducible nitric oxide synthase (iNOS), and TLR-4)
molecules, plasma HMGB1 levels, improved the morphology and decreased the number of activated
cerebral cortex microglia. Most importantly, the anti-HMGB1 antibodies reduced the delayed CVS
(Figure 1) and decreased the severity of neurological deficits, such as the impairment of coordinated
locomotor activity, which was assessed by an open field test with exposure to a novel environment [38].
Interestingly, the application of the anti-HMGB1 antibodies antagonized the sensitivity of the basilar
arteries to vasoconstriction induced by the increasing doses of thrombin [38]. The anti-HMGB1 antibody
treatment was effective in improving delayed CVS even if the antibody was applied 3 h after the SAH.
These results demonstrate the therapeutic and translational potential of HMGB1 neutralization that
can be achieved with delayed antibody treatment.
Another study aimed at the antibody-mediated antagonism of HMGB1 after SAH has shown that
the prevention of vascular smooth muscle cell (VSMC) phenotypic switching and vascular remodeling
may underlie the relieving of vasospasms [39]. The increased HMGB1 expression in the basilar artery
was found to be associated with the overexpression of embryonic smooth muscle myosin heavy chain
(Smemb) and osteopontin (OPN) and with a reduced expression of adult α-smooth muscle actin
(α-SMA) and smooth muscle-myosin heavy chain (SM-MHC), but these changes were reversed by
anti-HMGB1 antibodies [39]. Furthermore, anti-HMGB1 antibody administration was associated with
an improvement in cortical blood flow, reduction in cerebral edema, cortical apoptosis, microglial
activation and neurological impairments (assessed by modified Garcia scoring and beam balance
test) [39]. Similarly to the aforementioned study, the anti-HMGB1 antibody also significantly reduced
the expression of receptors for vasoconstrictive substances and reduced the threshold for a thrombin- or
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KCl-induced vasospasm in isolated basilar arteries after SAH [39]. Furthermore, authors demonstrated
that the phenotypic and vascular remodeling reversal to partly depend upon PI3K/Akt activity [39].
These evidences indicate not only the reversal of vasospastic changes, but also the prevention against
vascular remodeling and phenotypic switching, which result in the vessel wall thickening and reduced
luminal diameters, which pave the way to delayed cerebral ischemia and neurological decline.
Figure 1. Strategies targeting high mobility group box 1 (HMGB1)-mediated brain damage after an
aneurysmal subarachnoid hemorrhage (aSAH). Summary of the pharmacological strategies to block
HMGB1 in SAH. Blocking HMGB1 with multiple agents reduced cerebral vasospasm and brain damage
after SAH.
2.4. Subarachnoid Hemorrhage and Blood–Brain Barrier
The blood–brain barrier (BBB) allows the passage of selective substances into the brain, which are
readily distributed to other body tissues. This specialized barrier consists of tightly sealed endothelial
cells of the cerebral vasculature, which are further supported by pericytes and astrocytic endfeet at the
abluminal side, thus limiting the direct access to the brain [40]. A great body of evidence suggests that
an early disruption of the BBB takes place after ischemic strokes, hemorrhagic strokes and subarachnoid
hemorrhages [41]. In an ischemia reperfusion stroke model, the BBB disruption was evident as early as
3 h after reperfusion, and it was consistent with the astrocytic endfeet swelling and detachment from
the basement membranes and the disruption of endothelial tight junctions, as detected by electron
microscopic examination [42]. Shi and colleagues have shown the dynamics of BBB disruption after
ischemia-reperfusion injury in a mouse model of transient focal cerebral ischemia. An early breach of
the BBB was evident within 30 min after reperfusion by a small tracer of about 3kDa and within 3 h by
plasma IgG (of about 150 kDa), however, very large molecules of around 2000 kDa were evident only
at 24 h post-ischemia-reperfusion [43]. Interestingly, the very early breach of the BBB was mediated by
cytoskeletal rearrangements, leading to endothelial retraction, and later on by the disruption of the
endothelial junctional proteins by matrix metalloproteinase-9 (MMP-9) [43]. A great body of evidence
suggests that the increased levels of HMGB1 in the CSF and in the systemic circulation, after ischemic
and hemorrhagic strokes, are due to the release of HMGB1 from damaged cells that gains entry into
these compartments through the disrupted BBB. BBB impairment is more severe in the ischemic part of
the brain [10]. Anti-HMGB1 antibody targeting HMGB1 prevented the BBB disruption, probably by
reducing the expression of pro-inflammatory molecules and inhibiting the activation of glial cells [42].
Apart from anti-HMGB1 antibodies, the HMGB1 can be antagonized by glycyrrhizic acid, HMGB Box
A, soluble RAGE (sRAGE), ethyl pyruvate and recombinant thrombomodulin. After aSAH, it has
been shown that the early brain injury caused due to cerebral edema, which stems from early BBB
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disruption, leads to a poor clinical outcome [44]. The BBB disruption has been shown to be reduced
after antagonizing HMGB1 and reducing cerebral edema in SAH animal models [39].
2.5. Soluble RAGE Protected against EBI
The multiligand receptor RAGE also exists as a soluble receptor form that results from the
proteolytic cleavage of membranous RAGE lacking intracellular domains, or through alternate
splicing [45]. Soluble RAGE acts as a competitive inhibitor of RAGE by interacting with its cognate
ligands and thus, culminates and limits RAGE-mediated cellular signaling, cellular dysfunction
and damage [45]. Consequently, soluble RAGE (sRAGE) can be used to sequester HMGB1. RAGE
expression can be upregulated by its ligands such as HMGB1 in a positive feedback loop [46]. Both
HMGB1 and its receptor RAGE are upregulated in the brain after aSAH. The expression of RAGE
was particularly upregulated on neurons and microglia after the experimental SAH in rats and
was correlated with the increased expression of p65, suggesting a main role of RAGE in mediating
inflammation [47]. Consequently, the application of post-SAH CSF from patients or rats induced the
RAGE expression and reduced the viability of neuronal cultures. Interestingly, the administration of a
recombinant soluble form of RAGE to interfere with HMGB1 signaling reduced neuronal cell death
both in vitro and in vivo [48]. These data are consistent with a previously described finding suggesting
that interference with the HMGB1-signaling pathway protects against EBI. Table 1 (below) summarizes
all the experimental agents employed to neutralize the effects of HMGB1 in different animal models
of SAH.
Int. J. Mol. Sci. 2020, 21, 2709 7 of 14
Table 1. HMGB1 as a drug target in Subarachnoid Hemorrhage.
Sr. No. Author/Year Study Type(Animal Models)
HMGB1 Inhibitor
(ip/ICV) Dose Key Results
1 An et al. 2018 [34] Rat Endovascularperforation model AG 490
5 mM in 2 mL DMSO, ICV
30 min before SAH
Reduced apoptosis, edema, improved
neurological score
2 Ieong et al. 2018 [33] Rat Pre-chiasmatichemorrhage model Glycyrrhizin
15 mg/Kg after SAH, 6 h, 12
h, 18 h, ip
Reduced apoptosis, edema, improved
neurological score
3 Li et al. 2017 [32] Rat SAH modelDouble hemorrhage Glycyrrhizic acid 10 mg/Kg OD for 3 days, ip
Improved neurologic function,
prevented CVS and inflammatory
cytokines expression
4 Zhang et al. 2016 [30] Pre-chiasmatichemorrhage model Resveratrol
60 mg/Kg in 1% DMSO 2 h
and 12 h after SAH, ip
Reduced apoptosis, edema,
neurological impairment
5 Chang et al. 2015 [28] Rat SAH modelDouble hemorrhage 4OGOMV
100/200/400 µg/Kg/day
starting 1 h post SAH for 7
days through mini
osmotic pump
Improved CVS, neurological deficits,
reduced expression of inflammatory
mediators and neuronal apoptosis
6 Haruma et al. 2016 [38] Rat SAH modelSingle hemorrhage Anti-HMGB1 Antibody
mAb (IgG2a) 1 mg/Kg twice
with 24 h interval, iv
Improved CVS, neurological deficits,
reduced expression of inflammatory
mediators and receptors for
vasospastic mediators
7 Chang et al. 2016 [29] Rat SAH modelDouble hemorrhage Rhinacanthin
100/200/400 µmol/Kg/day
orally in corn oil starting at
1 h after SAH
Reduced apoptosis, improved CVS,
neurological deficits, reduced
inflammatory mediator expression
8 Chang et al. 2014 [27] Rat SAH modelDouble hemorrhage Purpurogallin
100/200/400µg/Kg/day
starting 1 h after SAH
through mini osmotic
pumps for 5 days
Reduced CVS, inflammatory mediators
expression and improved
neurological deficits
9 Wang et al. 2019 [39] Rat Endovascularperforation model Anti-HMGB1 Antibody
mAb 1 mg/Kg twice with a
24 h interval after SAH, iv
Reduced CVS, VSMCs phenotype
switching & remodelling, brain edema,
apoptosis, neurological deficits
10 Chen et al. 2018 [35] Rat Endovascularperforation model GSK 872
6 µL of 25 mM GSK 872 in
1% DMSO after 30 min of
SAH, ICV
Reduced brain edema, improved
neurological scores and reduced
neuronal necroptosis
11 Xiong et al., 2020 [36] Rat Endovascularperforation model BMSCs derived exosomes
1 h after SAH, 200µg of
MSCs-Exo and PBS to final
volume of 200µL, iv
Reduced neurological deficits, brain
edema, BBB permeability, mortality,
apoptosis and inflammation
ip: intraperitoneal; ICV: intracerebroventricular; iv: intravenously; BMSCs: bone marrow derived mesenchymal stem cells; BBB: blood–brain barrier; DMSO: dimethylsulfoxide;
Exo: exosomes; CVS: cerebral vasospasm; VSMC: vascular smooth muscle cells; PBS: phosphate buffered saline.
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3. Discussion
HMGB1 is a highly conserved non-histone nuclear protein and an important prototypical protein
DAMP that is released both in the CSF and the systemic circulation in clinical and experimental
SAH. The interaction between HMGB1 and pattern recognition receptors leads to the activation of
downstream signaling pathways (including NF-κB pathways) and consequently to the expression of
multiple pro-inflammatory genes.
The treatment of CVS via smooth muscle relaxants, such as calcium antagonists, endothelin
receptor antagonists, and Rho-kinase inhibitors, does not significantly improve clinical outcomes.
The lack of beneficial effects of smooth muscle relaxants is due to the complex pathophysiology of
SAH, where the causal relation to the development of a delayed CVS is poorly understood. Both
brain and vascular inflammation are closely related to the development of EBI and a delayed CVS [49].
Recent experimental studies have shown that HMGB1 is released from vascular smooth muscle cells
and intracranial vessel walls, which may be the source of circulating HMGB1 as suggested in some
clinical studies [9]. A causal relationship between the HMGB1 release and CVS has been established
with in vitro experiments showing the reversal of a spastic vascular phenotype after treatment with
anti-HMGB1 antibodies [38]. The release of HMGB1 may induce the expression of pro-inflammatory
cytokines and vasoconstriction-inducing receptors, including PAR-1, TXA2 receptor, AT1 receptor
and the ETA receptor via interactions with pattern recognition receptors [38]. As an upstream event,
the HMGB1 release during an EBI could theoretically be an excellent target for the treatment of
both the EBI and the delayed CVS. Indeed, targeting HMGB1 with monoclonal antibodies or with
pharmacological agents have reversed the delayed CVS (Figure 1) in animal SAH models [38].
HMGB1 effects could be mediated by multiple receptors, including TLR-4, TLR-2 and RAGE.
Interestingly, these receptors have been shown to be involved in the inflammatory response after
the SAH [50–52]. For instance, the HMGB1 ligation of the TLR-4 has been shown to activate
MMP-9 (Matrix metalloproteinase-9), which contributes to early brain injury after an experimental
SAH [53]. Nevertheless, further investigations are needed to establish the exact receptor pathway that
is involved in the induction of delayed CVS. Intriguingly, on one hand the HMGB1 ligation of RAGE on
monocytes/macrophages has been shown to enhance the ischemic brain damage, and on the other hand,
HMGB1-signaling via RAGE drives an IL-10 release from M2-like macrophages (the anti-inflammatory
phenotype of macrophages). In line with this notion, serum HMGB1 levels measured within 24 h
after the aSAH showed a correlation with a latter increase in serum IL-10 levels measured on day 7
after the aSAH [21]. It is well known that anti-inflammatory mechanisms also upregulate in parallel
to pro-inflammatory mechanisms to limit the damage, however, it would be interesting to evaluate
further how these pro-inflammatory mechanisms are dominated by anti-inflammatory mechanisms,
and how they contribute towards different post-aSAH complications and clinical outcomes, as several
lines of evidence also report immunodepression after aSAH [21,54].
Anti-HMGB1 antibody treatment blocked the expression of pro-inflammatory cytokines (including
IL-6, TNF, and TLR-4, iNOS) and vasoconstriction-inducing receptors, and reversed the contractile
phenotype of the basilar artery and improved neurological outcomes [38]. Furthermore, HMGB1
has been implicated in vascular smooth muscle cell phenotype switching and vascular remodeling,
which may underlie the thickened vascular walls along with the reduced intraluminal diameter [39].
These changes ultimately lead to cerebral ischemia and neurological deficits [39]. These results
suggest that targeting HMGB1 may be a better option to treat delayed CVS than simply with smooth
muscle relaxants as previously done. Another possible mechanism of inflammation-mediated delayed
CVS is the expression of COX-2 in the vasculature. COX-2 is a target gene of NF-κB that can be
activated by HMGB1 via pattern recognition receptors. Thus, a continuous mobilization of HMGB1
from cerebral vessels, starting early after the aSAH, leads to the expression of pro-inflammatory
cytokines and receptors that in turn mediate the CVS. Anti-HMGB1 antibodies are perhaps a new
approach to interrupt this cascade of events and to induce a relaxed phenotype of smooth muscle cells,
and consequently reduce the CVS and improve the clinical outcomes.
Int. J. Mol. Sci. 2020, 21, 2709 9 of 14
Interestingly, different isoforms of HMGB1 exist after the extracellular release with distinct
functionalities and differences in their interactions with various receptors [20,55]. These differences
owe to the redox states of three cysteine residues (C23, C45 and C106) in the Box B of the HMGB1
molecule. For instance, when all of these cysteine residues are in a reduced thiolated state, HMGB1
activates RAGE and promotes CXCL12/CXCR4 signaling [55]; whereas the oxidized form of HMGB1
with disulfide linkages between C23–C45 has a greater propensity to activate TLR-2 and TLR-4 to
strongly upregulate inflammation [55]. Furthermore, a fully oxidized and sulphonated form is seen
during inflammation resolution and is inert [20]. Intriguingly, an oxidized form of HMGB1 has been
shown to play a neuroprotective role during the recovery phase of the SAH (day 14 after the SAH),
depicted by an inability to stimulate serum and CSF TNF-α upsurge and enhancing neurotrophin
expression, as opposed to a reduced form of HMGB1 [56]. Furthermore, the inhibition of HMGB1
and RAGE signaling during this delayed recovery phase after the SAH (day 14 after the SAH) was
associated with a decline in the neurotrophic growth factors (Nerve growth factor (NGF), Brain
derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF)) and a reduction
in neurogenesis as assessed by BrdU and DCX positive neurons [56]. The inhibition of RAGE by
FPS-ZM1 and HMGB1 by ethyl pyruvate and glycyrrhizin also enhanced brain water content and
the functional neurological impairment during this delayed recovery phase after SAH [56]. It would
be quite interesting to study the dynamics of these distinct isoforms over the course of early brain
injury and CVS after the SAH, and the impact of modulating these HMGB1 isoforms on inflammatory
changes and neurological function after an experimental SAH. As mentioned earlier, HMGB1–RAGE
signaling in macrophages has been shown to enhance ischemic brain damage as well as the secretion of
anti-inflammatory cytokine (IL-10 secreted by M2-type macrophages). It would be also quite interesting
to elucidate the dynamics of the structurally and functionally different isoforms of HMGB1 over the
entire course of early and delayed brain injury in SAH patients, and how they modulate the activity of
macrophages involving RAGE and other cognate receptors.
HMGB1 also contributes to coagulation, as depicted by the platelets’ aggregation upon the
ligation of RAGE, platelet activation and thrombus formation due to HMGB1/TLR-4 signaling and the
enhanced expression of tissue factor in monocytes and endothelial cells [57]. Intriguingly, during an
early brain injury after SAH, there is also evidence of microvasospasms and microthrombosis and the
degree of arteriolar constriction correlates with microthrombotic frequency [58]. These mechanisms
could compromise blood flow independently of cerebral perfusion pressure [58]. Furthermore,
Clazosentan was also found to be ineffective towards relieving these microvasospasms and improving
deficits in the experimental SAH rat model [59]. Previously, a failure of Clazosentan to improve the
clinical outcomes of SAH patients led to a renewed interest in exploring the additional mechanisms
of brain injury, other than angiographic vasospasm [3]. It might be a new beginning to explore
the underpinnings of microvasospasms and exploring the role of inflammation, as inflammation
and thrombosis cannot be segregated into distinct events independent of each other. It would be
interesting to study the implications of HMGB1 and its cognate receptors in the microvasospasms
and microthrombosis and the impact of modulating HMGB1 on the inflammation underlying these
events. Thrombomodulin has also been shown to scavenge HMGB1 [60] and it may be employed to
study its impact on CVS, microthrobosis and microvasospasms during EBI after aSAH. Altogether,
the aforementioned pieces of evidence suggest an indispensable role of HMGB1 after an aSAH and its
contribution to aSAH-led complications, especially CVS and poor neurological outcomes. Despite the
shift in the traditional paradigm, i.e., from CVS leads to DCI and poor outcomes, towards a complex
multifactorial pathophysiology involving varied contributions from EBI, cortical spreading depression
and inflammation, there is still a population of CVS patients who develop DCI and poor outcomes [61].
Furthermore, inflammation is associated with EBI, CVS, DCI and poor outcomes and the inhibition of
HMGB1-mediated inflammation could be promising to benefit aSAH patients at increased risk of these
complications and poor outcomes.
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Due to the presence of an intact blood–brain barrier, pharmacological agents have limited excess
to the brain. However, during pathological conditions including cerebral ischemia or subarachnoid
hemorrhage, disrupted blood–brain barrier facilitates the access of pharmacological agents to the
injured brain. Although there are differences in different rodent SAH models and also differences of
the BBB among the various animals used for the SAH, the ischemic insult induces a massive disruption
of the BBB [40,41,62]. Furthermore, the observance of the pharmacological effects of anti-HMGB1
antibodies at the CNS level also suggest their access through the permeable BBB. Reduction in the
permeability of the BBB after the administration of anti-HMGB1 antibodies may also argue against
any further access of these antibodies through the BBB, but may also reflect the culmination of the
effects which may no longer be required, suggesting healing based self-termination of the CNS effects.
However, pharmacokinetics of anti-HMGB1 antibodies and other anti-HMGB1 molecules remain to be
elucidated in these SAH animal models. Recently, radiolabeled antibodies have been imaged to quantify
the penetration through the blood–brain barrier. It is also known that antibody penetration across the
BBB is more into the brain areas which are severely affected by tumors [63]. However, as mentioned
above, strokes may lead to the massive disruption of the BBB and interestingly, ischemic brain regions
have also shown greater penetration through the BBB [10]. Glycyrrhizic acid has been evaluated
as an adjunctive anti-inflammatory agent to treat depression in a randomized-placebo-controlled
clinical trial [64], but similar studies in aSAH could be possible. There is a need to characterize the
pharmacokinetics and bioavailability of the drugs at the CNS level (e.g., in the CSF), particularly in
patients who underwent extraventricular drain placement. Altogether, the experimental strategies
antagonizing HMGB1 await clinical translation to benefit aSAH-afflicted patients by improving their
outcomes, as pharmacological interventions in the context of aSAH are still scarce.
4. Conclusions
The experimental data suggest that HMGB1 inhibition is a promising strategy to reduce
SAH-related brain damage and CVS. The brain accessibility of pharmacological agents targeting
HMGB1 need to be evaluated in detail. Clinical studies are needed to validate this strategy in humans,
and aid in the development of potential treatment options that are much needed in aSAH.
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